# ENERGIZE (NCT03661320)

> A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03661320
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Urinary Bladder Neoplasms; Muscle-Invasive Bladder Cancer
- Interventions: Nivolumab; Gemcitabine; Cisplatin
- Enrollment: 855
- Primary outcome: Pathological Complete Response (pCR) rate, in all randomized participants
- Primary outcome: Event-Free Survival (EFS), in all randomized participants

## Indexed commentary on ENERGIZE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 79
- YouTube: 16
- Podcasts: 13
- X videos: 2
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=energize-nct03661320

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03661320", "email": "<work email>"}; the inbox owner confirms by the emailed link.